Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;13(2):e70090.
doi: 10.1002/prp2.70090.

The Genetic Polymorphisms of rs161620 and rs2229611 in G6PC 3'UTR Are Associated With Metformin Efficacy in Chinese Type 2 Diabetes Mellitus

Affiliations

The Genetic Polymorphisms of rs161620 and rs2229611 in G6PC 3'UTR Are Associated With Metformin Efficacy in Chinese Type 2 Diabetes Mellitus

Cuilin Li et al. Pharmacol Res Perspect. 2025 Apr.

Abstract

Metformin is a classical oral hypoglycemic drug, often recommended as the first-line therapy for type 2 diabetes mellitus (T2DM). Previous research has shown that the efficacy of metformin is associated with the genetic polymorphisms of patients. Considering the role of G6PC in gluconeogenesis and glycogenolysis, this study aims to investigate the association of G6PC rs161620 and rs2229611 with metformin efficacy in T2DM patients who take metformin only. According to the decrease of HbA1c, 116 T2DM patients receiving metformin monotherapy were divided into two groups: response group (the decrease of HbA1c by at least 1.5% after 3 months) and non-response group (the decrease of HbA1c < 1.5%). SNPscan technology was used to genotype. There were significant differences in rs161620 and rs2229611 presented in genotype frequency (p = 0.027 both) between the response group and the non-response group. According to the results of logistic analysis, the genetic polymorphisms of G6PC rs161620 or rs2229611 could influence the hypoglycemic effect of metformin in T2DM patients. We found that the decreasing values of PBG and HbA1c in G6PC rs161620 (C > A) or rs2229611 (T > C) mutants were significantly more than those in wild-type individuals, which means the more effective genotypes of metformin are CA/AA of rs161620 and TC/CC of rs2229611. This study suggested that the G6PC rs161620 and rs2229611 genetic polymorphisms were significantly associated with metformin efficacy in Chinese T2DM patients.

Keywords: G6PC; metformin; polymorphism; rs161620; rs2229611; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The decreases of PBG value and HbA1C value in T2DM patients after metformin treatment. (a) the decrease of PBG value in G6PC rs161620 (C >A ) mutants was significantly greater than that in wild‐type individuals. (b) the decrease of HbA1c value in G6PC rs161620 (C > A) mutants was significantly greater than that in wild‐type individuals. (c) the decrease of PBG value in G6PC rs2229611 (T > C) mutants was significantly greater than that in wild‐type individuals. (d) the decrease of HbA1c value in G6PC rs2229611 (T >C ) mutants was significantly greater than that in wild‐type individuals. Data are shown as mean ± SD. *p < 0.05 compared with the wild type (n = 116). **p < 0.01 compared with the wild type (n = 116).

Similar articles

References

    1. Sun H., Saeedi P., Karuranga S., et al., “IDF Diabetes Atlas: Global, Regional and Country‐Level Diabetes Prevalence Estimates for 2021 and Projections for 2045,” Diabetes Research and Clinical Practice 183 (2022): 109119, 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Flory J. and Lipska K., “Metformin in 2019,” JAMA 321, no. 19 (2019): 1926–1927. - PMC - PubMed
    1. Cook M. N., Girman C. J., Stein P. P., and Alexander C. M., “Initial Monotherapy With Either Metformin or Sulphonylureas Often Fails to Achieve or Maintain Current Glycaemic Goals in Patients With Type 2 Diabetes in UK Primary Care,” Diabetes/Metabolism Research and Reviews 24, no. 4 (2007): 350–358, 10.1111/j.1464-5491.2007.02078.x. - DOI - PubMed
    1. Florez J. C., “The Pharmacogenetics of Metformin,” Diabetologia 60, no. 9 (2017): 1648–1655, 10.1007/s00125-017-4335-y. - DOI - PMC - PubMed
    1. van Schaftingen E. and Gerin I., “The Glucose‐6‐Phosphatase System,” Biochemical Journal 362, no. Pt 3 (2002): 513–532, 10.1042/0264-6021:3620513. - DOI - PMC - PubMed

Supplementary concepts

LinkOut - more resources